NCT06571916 Brief Skills for Safer Living (Brief-SfSL)
| NCT ID | NCT06571916 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Unity Health Toronto |
| Condition | Suicide Prevention |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-11-17 |
| Primary Completion | 2028-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-11-17 with a primary completion date of 2028-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this project is to assess the efficacy of Brief-Skills for Safer Living (Brief-SfSL) in a randomized control trial. The investigators will be testing 150 participants Canada-wide, half of which will be randomized to receive Brief-SfSL (B-TAU) and the other half will be randomized to receive Brief-SfSL after a 3 month waitlist (WL-TAU). The main questions this study seeks to answer are: * Is B-TAU more efficacious than WL-TAU for reducing suicidal thoughts at 3 months? * Is B-TAU more efficacious than WL-TAU at 3 months for reducing depression severity, anxiety, and anhedonia? * Is B-TAU more efficacious than WL-TAU at 3 months for improving social connectedness, emotional regulation, functioning (work, life, social), executive control and social problem-solving? * Are adverse events equivalent between B-TAU and WL-TAU at 3 months?
Eligibility Criteria
Inclusion Criteria: * Suicidal ideation in the past week * Access to a computer or phone with a camera * Access to internet * Access to an emergency contact and hospital within commuting distance * Not receiving other psychotherapy/counselling services concurrently * Willing to have the session recorded to determine therapy fidelity * Any psychiatric diagnosis is allowed * Follow-up visits with a psychiatrist and/or family doctor where a psychotherapeutic modality (e.g., Dialectical Behavioural Therapy, psychodynamic therapy, etc.) is not being used are allowable Exclusion Criteria: * Inability to undergo psychotherapy in English * Presence of cognitive impairment that would limit consent and understanding of Brief Skills for Safer Living or study procedures * Active psychosis that impairs capacity to consent, understand study procedures, or participate * Unwilling or unable to provide informed consent * Previously enrolled in the Brief-SfSL pilot study * Unwilling or unable to communicate verbally
Contact & Investigator
Sakina Rizvi, PhD, MACP
PRINCIPAL INVESTIGATOR
Unity Health Toronto
Frequently Asked Questions
Who can join the NCT06571916 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Suicide Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06571916 currently recruiting?
Yes, NCT06571916 is actively recruiting participants. Contact the research team at anna.kiriakidis@unityhealth.to for enrollment information.
Where is the NCT06571916 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06571916 clinical trial?
NCT06571916 is sponsored by Unity Health Toronto. The principal investigator is Sakina Rizvi, PhD, MACP at Unity Health Toronto. The trial plans to enroll 150 participants.